Terms ending in 2041
Every in-force patent on Ablynx N.V.'s record whose computed term ends in 2041, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,840,566 | Methods of Treating Asthma with Polypeptides Targeting IL-13 and TSLP In force · Medium confidence | N.V., Ablynx | In force | Medium confidence | |
| US 11,897,951 | POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-6 AND TNF-a In force · High confidence | Ablynx N.V. | In force | High confidence | |
| US 11,932,702 | Polypeptides Comprising Immunoglobulin Single Variable Domains Targeting GLYPICAN-3 and T Cell Receptor In force · High confidence | Ablynx N.V. | In force | High confidence | |
| US 12,709,646 | Polypeptides Comprising Immunoglobulin Single Variable Domains Targeting GLYPICAN-3 and T Cell Receptor In force · Medium confidence | Ablynx N.V. | In force | Medium confidence |
4 of 4 patents shown. Soonest term end first, then patent number.
3 of these are in force and held by Ablynx N.V..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.